Bio

Bio

Intern, Ministry of Health, Kenyatta National Hospital

1986-1990 Pathology Resident, Ministry of Health, Kenyatta National Hospital

1990-2001 Lecturer, Consultant Pathologist, Dept of Human Pathology, University of

Nairobi/Kenyatta National Hospital

2003 to date Senior Lecturer, Consultant Pathologist, Dept. of Human

Pathology/Kenyatta National Hospital

Publications


2013

Muchiri, L.  2013.  CRYOTHERAPY FOLLOWING VIA/VILI IN KHWISERO WESTERN KENYA: LESSON FROM THE FIELD AFFECTING POLICY AND PRACTICE. East African Medical Journal. October 2013(2013):318-324.

2012

Muchiri LW, Kigondu CBS, EBBATM.  2012.  Risk Association between Human Leucocyte Antigen (HLA) and cervical neoplasia in Kenyan women. . Afr. J. Pharmacol. Ther.. 1(1):8-13.

2011

De Vuyst, H, Parisi MR, Karani A, Mandaliya K, Muchiri L, Vaccarella S, Temmerman M, Franceschi S, Lillo F.  2011.  The prevalence of human papillomavirus infection in Mombasa, Kenya. Abstract

A human papillomavirus (HPV) prevalence survey was done in Mombasa, Kenya, to improve the knowledge of HPV prevalence and genotype distribution in sub-Saharan African countries overall, and in women of different ages. METHODS: HPV prevalence was assessed using PCR in women older than 15 years attending family planning and mother-child care services. RESULTS: Among 496 women, HPV prevalence was high (42.3%; 95% CI: 37.9-46.8; world age-standardized). Moreover, 46% of HPV-positive women harbored multiple-type infections. The most common types were HPV58 (10.5% of women), HPV16 (7.7%), HPV53 (6.7%), HPV18 (4.6%), and HPV6 (4.4%), and the prevalence of any high-risk HPV type was 28.8%. HPV prevalence was elevated among all age-groups (range 36.4-45.7%). Independent associations with HPV positivity were found for being in a polygamous marriage (OR = 1.7) and lifetime number of sexual partners (OR for ≥ 3 vs. 1 = 1.5), although they were of only borderline statistical significance. CONCLUSIONS: These findings differ from other world regions, showing a high HPV burden in all age-groups with a high proportion of multiple-type infections. Our data strengthen the urgency of HPV vaccination in Kenya but also highlight the elevated number of women who would have positive results in an HPV-based screening program in the country.

2010

De Vuyst, H, Parisi MR, Karani A, Mandaliya K, Muchiri L, Vaccarella S, Temmerman M, Franceschi S, Lillo F.  2010.  Cancer Causes & Control > Vol. 21, No. 12, December 2010. Website

2008

Lucy Muchiri, Gathari Ndirangu, CKPGJMBEMT.  2008.  HIV infection and cervical neoplasia in a Kenyan semi-urban population., October, 2008.. 9th APECSA Conference. , Mombasa, Kenya
Kalebi A, Muchiri L, GGRD.  2008.  Medical Students and the Autopsy: A survey of medical students in a Nairobi Medical School., October, 2008. 9th APECSA Conference. , Mombasa, Kenya
Muchiri L, Rajab J, LG.  2008.  The Breast Cancer Awareness month: The Mater Hospital Experience., October, 2008 . 9th APECSA Conference. , Mombasa, Kenya
Muchiri, L.  2008.  The Utility of a rapid test for syphilis in an ART clinic in Tigoni , January. Annual Scientific meeting of Sexually Transmitted Infections and HIV/AIDS. , Nairobi, Kenya

2007

Sang CK, Sekadde-Kigondu C, ML.  2007.  Fine needle aspiration cytology of thyroid nodules at Kenyatta National Hospital, Nairobi.. East Afr Med J. . 84(3):117-20.

2006

Nyagol, J, Nyong'o A, BYAKIKA B, Muchiri L, Cocco M, de Santi MM, Spina, D; Bellan C, Lazzi S, Kostopoulos I, Luzi P, Leoncini L.  2006.  Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.. Abstract

To report the expression of estrogen receptors, progesterone receptors and human epidermal growth factor receptor (Her-2/neu) in 158 Kenyan women with breast cancer and correlation with other prognostic indicators in this high-risk group. This study stressed the importance of routine assessment of the steroid receptors and Her-2/neu as a mode of therapeutic selection of patients for antihormonal or targeting monoclonal antibody (Herceptin) therapy, directed at the juxtamembrane domain of Her-2/neu protein in the developing countries such as Kenya. STUDY DESIGN: The study population consisted of 158 female patients with histologically confirmed breast carcinoma seen at the pathology department of The Nairobi Hospital. An immunohistochemical (IHC) study of ER, PR and Her-2/neu was conducted, followed by fluorescent in situ hybridization (FISH) validation for Her-2/neu gene amplification in cases initially scored as positive 2+ with IHC. Mastectomy samples registered at the pathology department of The Nairobi Hospital were used for this study. The study was approved by the institution's ethical review committee and informed consent obtainedfrom the concerned patients. RESULTS: In the studied cohort, positivity for both hormonal receptors and Her-2/neu was noted in 10 (6.33%) cases and negativity in 44 (27.85%) cases. Conversely, Her-2/neu negativity was noted in 32 (20.25%) cases with both steroid receptors positive and Her-2/neu positivity with both steroid receptors negative in 20 (12.66%) cases. Overall, no predictive factor was found in the Her-2/neu amplified 31/153 (20.26%) cases completely assessed with IHC and FISH. Grade III invasive ductal carcinomas, however, had a high prevalence of Her-2/neu overexpression. Association of both menopausal status (p = 0.044) and progesterone receptor status (p = 0.004) with high grade tumors were found to be statistically significant at 95% CI (p < 0.5). Consistent with other studies, Her-2/neu overexpression in this cohort was 20.26%. CONCLUSION: Her-2/neu positivity may activate ER expression through signaling kinases, and the combined target of mitogenic estrogen plus the monoclonal antibody therapy against Her-2/neu-overexpressing tumors expand chances of survival for patients in developing countries such as Kenya. The cost factor for these tests, selection for appropriate combined therapies and lack of awareness were noted as limiting factors for access to basic health care service and resulted in advanced tumor grade at time of patient presentation.

  2006.  The impact of HIV infection on cervical neoplasia in a Kenyan Semi-urban population., 16 September. The Centennial IAP Congress.. , Montreal, Canada
Nyagol J, Leucci E, ODFTSTAGCF, Palummo N, Pacenti L SSGMLPLGRDPL.  2006.  The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesis. Cancer Biol Ther. . 5(6):684-90.
Sang CK, Sekadde-Kigondu C, ML.  2006.  Correlation between cytology and thyroid function test. . East Afr Med J.. 83(10):533-8.

2005

De Vuyst H, Claeys P, NMSDSVMBTSLSP.  2005.  Comparison of pap smear, visual inspection with acetic acid, human papillomavirus DNA-PCR testing and cervicography.. Int J Gynaecol Obstet. . 89(2):120-6.

2003

De Vuyst H, Steyaert S, VRCLP, Muchiri L, Sitati S VQKVMTSWBE.  2003.  Distribution of human papillomavirus in a family planning population in nairobi, kenya.. Sex Transm Dis. . 30(2):SexTransmDis..
L., M.  2003.  Laboratory diagnosis of Hodgkin's disease: what are the challenges? East Afr Med J.. 80(3):117-8..

2002

Wango EO, Tabifor HN, MLWS-KMDWC.  2002.  Progesterone, estradiol and their receptors in leiomyomata and the adjacent normal myometria of black Kenyan women.. Afr J Health Sci.. 9(3-4):123-8.

2001

LW., M.  2001.  Role of fine needle aspiration in the diagnosis of neoplasms.. East Afr Med J.. 78(5):225.

1999

Temmerman M, Tyndall MW, KCMQNPLW.  1999.  Risk factors for human papillomavirus and cervical precancerous lesions, and the role of concurrent HIV-1 infection.. Int J Gynaecol Obstet.. 65(2):171-81.

1998

1993

Muchiri LW, Penner DW, ARFSJ.  1993.  . Role of fine-needle aspiration biopsy in the diagnosis of breast lumps at the Kenyatta National Hospital.. East Africa Med. Journal. 70(4):31-3..

UoN Websites Search